Kaposi's sarcoma echocardiograph and ultrasound

Jump to navigation Jump to search

Kaposi's sarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Kaposi's sarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Kaposi's sarcoma echocardiograph and ultrasound On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Kaposi's sarcoma echocardiograph and ultrasound

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Kaposi's sarcoma echocardiograph and ultrasound

CDC on Kaposi's sarcoma echocardiograph and ultrasound

Kaposi's sarcoma echocardiograph and ultrasound in the news

Blogs on Kaposi's sarcoma echocardiograph and ultrasound

Directions to Hospitals Treating Kaposi's sarcoma

Risk calculators and risk factors for Kaposi's sarcoma echocardiograph and ultrasound

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[3]

Overview

There are no specific echocardiography/ultrasound findings associated with Kaposi's sarcoma.

Echocardiography/Ultrasound

  • There are no specific echocardiography/ultrasound findings associated with Kaposi's sarcoma.
  • However, echocardiograph is necessary if liposomal doxorubicin is used as therapy, since this medication causes cardiomyopathy. Routine echocardiographs may need to be done throughout therapy, typically once every 3 months.[1]

References

  1. Sadurska E (2015). "Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors". Pediatr Cardiol. 36 (6): 1112–9. doi:10.1007/s00246-015-1176-7. PMC 4495714. PMID 25939787.


Template:WH Template:WS